Aptevo Therapeutics Announces Trispecific Program Progress; APVO451 IND in 1H2027

What Happened Aptevo Therapeutics Inc. filed an 8-K on September 24, 2026, announcing progress on its next‑generation trispecific antibody programs. The company said it is optimizing several trispecific candidates for reliable, scalable manufacturing and expects to enter Investigational New Drug (IND)‑enabling studies for its lead candidate, APVO451, in the first half of 2027.

Key Details

• Announcement date: September 24, 2026 (press release attached to the 8-K).
• Lead candidate: APVO451; IND‑enabling studies targeted to begin in 1H2027.
• Program focus: optimization of multiple trispecific candidates for reliable, scalable manufacturing.
• Corporate filing: information disclosed under Item 8.01 (Other Events) of the Form 8‑K.

Why It Matters This update signals preclinical and manufacturing progress for Aptevo’s trispecific platform and a concrete near‑term development milestone (IND‑enabling studies for APVO451). For investors, moving toward IND studies is a key step that can potentially enable future human clinical trials and value inflection points; however, the filing reports intent and timing, not clinical data or regulatory filings (an actual IND submission or FDA clearance was not announced).